Carlson Capital Management Abb Vie Inc. Transaction History

Carlson Capital Management

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	BUY	$137.6 - $154.97 $155,075 - $174,651	1,127 Added 55.06%	3,174 $491,000
Q3 2023 Nov 21, 2023	SELL	$133.59 - $154.65 $20,439 - $23,661	-153 Reduced 6.95%	2,047 $305,000
Q2 2023 Jul 24, 2023	BUY	$132.51 - $164.9 $15,503 - $19,293	117 Added 5.62%	2,200 $296,000
Q1 2023 Apr 17, 2023	SELL	$144.61 - $166.54 $12,581 - $14,488	-87 Reduced 4.01%	2,083 $331,000
Q4 2022 Feb 03, 2023	SELL	$138.31 - $165.87 $53,802 - $64,523	-389 Reduced 15.2%	2,170 $350,000
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $1,878 - $2,155	14 Added 0.55%	2,559 $343,000
Q2 2022 Jul 18, 2022	SELL	$137.62 - $174.96 $24,358 - $30,967	-177 Reduced 6.5%	2,545 $390,000
Q1 2022 May 24, 2022	BUY	$131.98 - $163.75 $74,040 - $91,863	561 Added 25.96%	2,722 $441,000
Q4 2021 Jan 14, 2022	BUY	$107.43 - $135.93 $2,256 - $2,854	21 Added 0.98%	2,161 $293,000
Q3 2021 Oct 12, 2021	BUY	$106.4 - $120.78 $7,873 - $8,937	74 Added 3.58%	2,140 $231,000
Q2 2021 Jul 12, 2021	BUY	$105.21 - $117.21 $4,103 - $4,571	39 Added 1.92%	2,066 $233,000
Q1 2021 Apr 12, 2021	BUY	$102.3 - $112.62 $207,362 - $228,280	2,027 New	2,027 $219,000

3,795

1.28B

13M

9.82M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $308B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Carlson Capital Management, based on Form 13F filings with the SEC.

Stay updated on Carlson Capital Management with notifications on news.